Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 71% of modeled bridge. Strengths: Occupancy Rate. Risks: Revenue per Bed, Commercial Payer %. Risk-adjusted uplift: $1.4M (vs $2.0M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $752K | $752K | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $724K | $21K | $744K | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $115K | $342K | $457K | $1.4M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $24K | $24K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 42.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $188K | $376K | $564K | $752K | $752K | $752K | $752K |
| Denial Rate Reduction | $0 | $186K | $372K | $558K | $744K | $744K | $744K | $744K |
| A/R Days Reduction | $0 | $152K | $305K | $457K | $457K | $457K | $457K | $457K |
| Clean Claim Rate | $0 | $12K | $24K | $24K | $24K | $24K | $24K | $24K |
| Cumulative | $0 | $539K | $1.1M | $1.6M | $2.0M | $2.0M | $2.0M | $2.0M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $2.0M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 92% / 26.2x | 97% / 29.5x | 101% / 32.8x | 103% / 34.4x | 105% / 36.0x |
| 9.0x | 87% / 22.9x | 92% / 25.9x | 96% / 28.8x | 98% / 30.2x | 100% / 31.7x |
| 10.0x | 83% / 20.3x | 87% / 22.9x | 91% / 25.6x | 93% / 26.9x | 95% / 28.2x |
| 11.0x | 79% / 18.2x | 83% / 20.6x | 87% / 22.9x | 89% / 24.1x | 91% / 25.3x |
| 12.0x | 75% / 16.4x | 79% / 18.6x | 83% / 20.8x | 85% / 21.9x | 87% / 22.9x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 66% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 2.2x, adding 6.3 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $689K | — | $689K | 1.8% |
| Year 1 | $710K | +$1.3M | $2.0M | 5.4% |
| Year 2 | $731K | +$2.0M | $2.7M | 7.2% |
| Year 3 | $753K | +$2.0M | $2.7M | 7.3% |
| Year 4 | $775K | +$2.0M | $2.8M | 7.3% |
| Year 5 | $799K | +$2.0M | $2.8M | 7.4% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $376K | $564K | $752K | $902K |
| Denial Rate Reductio | $372K | $558K | $744K | $893K |
| A/R Days Reduction | $229K | $343K | $457K | $549K |
| Clean Claim Rate | $12K | $18K | $24K | $29K |
| Total | $989K | $1.5M | $2.0M | $2.4M |
Peer Context — Where This Hospital Sits
Key metrics vs 40 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 1.8% | -11.0% | -0.2% | 12.2% | P55 |
| Net-to-Gross | 40.9% | 23.3% | 29.0% | 42.0% | P72 |
| Occupancy | 79.9% | 46.2% | 64.1% | 74.7% | P85 |
| Rev/Bed | $361K | $412K | $1.2M | $1.5M | P18 |
| Exp/Bed | $355K | $534K | $1.2M | $1.6M | P12 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.